GenomePlex™ whole genome amplification (WGA) point of use kit (Rubicon Genomics, Inc.) complements Rubicon's WGA in-house service business that was launched earlier this year. A proprietary in-vitro method is used to convert very small amounts of genomic DNA into OmniPlex™ amplifiable libraries. The kits focus on the most common samples sizes and concentrations. They are designed for ready to use at pharmaceutical companies, institutions and universities unable to use the WGA custom amplification services because of time, cost, or prohibition of export of patient samples. The first launched GenomePlex kits contain proprietary reagents and protocol sufficient for 50 WGA reactions, each generating up to 10 μg of amplified DNA in less than 4 hours. The protocol is simple, and the amplified DNA has been validated on multiple high throughput genotyping and sequencing platforms. Amplification product is not detected using GenomePlex in the absence of input DNA.